SCHEMBL9931924

SCHEMBL9931924

Cn1c(-c2cc(NCCS(C)(=O)=O)ncc2Cl)nc2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
KDM4E B2RXH2 4/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 2/20 0.41
MAPT P10636 3/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ATM Q13315 2/20 0.39
HCRTR1 O43613 1/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
HTT P42858 1/20 0.39
CASP7 P55210 1/20 0.39
HBB P68871 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TLR9 Q9NR96 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
FGFR1 P11362 6/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9933111 0.91 CA1 (0.42) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL9968291 0.86 KMT2A (0.45) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL9931758 0.85 MKNK1 (0.48) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL9932095 0.85 CCNT1 (0.45) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL9932409 0.80 MEN1 (0.41) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL9931505 0.77 SMO (0.60) KMT2AKDM4EALDH1A1NPSR1GAA
SCHEMBL9971209 0.75 MEN1 (0.39) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL1533963 0.75 MEN1 (0.62) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL9933194 0.73 SMO (0.50) MEN1KMT2APDE10A
SCHEMBL20867533 0.73 MEN1 (0.52) MEN1KMT2AKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157471-A1 BENZIMIDAZOLE DERIVATIVES PFIZER INC. (US) 2012-06-21 US disclosed
US-20120157471-A1 BENZIMIDAZOLE DERIVATIVES PFIZER INC. (US) 2012-06-21 US disclosed
US-20120157471-A1 BENZIMIDAZOLE DERIVATIVES PFIZER INC. (US) 2012-06-21 US disclosed
WO-2011027249-A2 BENZIMIDAZOLE DERIVATIVES PFIZER INC. (US) 2011-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157471-A1 BENZIMIDAZOLE DERIVATIVES SMO, RB1, GLI1 MEN1 1168/4885KMT2A 310/4885KDM4E 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.